Join us for the first in a series of webinars highlighting the groundbreaking testing offered by CellTrend Laboratory in Germany.

Emerging research is uncovering the role of a novel class of biomarkers: autoantibodies, which are antibodies that mistakenly target the body’s own receptors in complex neuroimmune and autonomic disorders such as Myalgic Encephalomyelitis (M.E.), Postural Orthostatic Tachycardia Syndrome (POTS), Small Fibre Neuropathy (SFN), and Long COVID.

In this session, Professor Dr. Kai Schulze-Forster, CEO of CellTrend, will explore the pioneering work of MD scientists Professors Carmen Scheibenbogen and Uwe Wirth, whose research laid the foundation for these innovative markers.

The webinar will also cover:
– How autoantibodies may disrupt receptors that regulate heart rate, blood flow, neurotransmission, and immune balance, contributing to hallmark symptoms in these conditions.
– The history and discovery of these biomarkers.
– The advanced immunoassays developed in collaboration with Charité University Hospital, Berlin, which enable clinicians and researchers to measure these specific antibodies and gain valuable physiological insights.

Key markers discussed will include:
– Beta-1 and Beta-2 adrenergic receptor autoantibodies
– Muscarinic M3 and M4 acetylcholine receptor autoantibodies

Discover how these insights are shaping research and patient care in chronic neuroimmune conditions.
Learn more about CellTrend’s testing: aonm.org/celltrend/